New Data on Alzstatin for Preventive Treatment Against Alzheimer's Presented at Alzheimer's Conference CTAD - Seite 2
"We see a great interest for Alzstatin in the field as it offers access to a potentially preventive, non-invasive oral therapy for patients, and these new data further strengthen the commercial opportunities for our research platform Alzstatin," said Martin Jönsson, CEO of AlzeCure Pharma.
The abstract is available om AlzeCure's website (https://www.alzecurepharma.se/en/presentations-and-interviews/).
For more information, please contact
Martin Jönsson, CEO
Tel: +46 707 86 94 43
martin.jonsson@alzecurepharma.com
About AlzeCure Pharma AB (publ)
AlzeCure® is a Swedish pharmaceutical company that develops new innovative small molecule drug therapies for the treatment of severe diseases and conditions that affect the central nervous system,
such as Alzheimer's disease and pain - indications for which currently available treatment is very limited. The company is listed on Nasdaq First North Premier Growth Market and is developing
several parallel drug candidates based on three research platforms: NeuroRestore®, Alzstatin® and Painless.
NeuroRestore consists of two symptomatic drug candidates where the unique mechanism of action allows for multiple indications, including Alzheimer's disease, as well as cognitive disorders
associated with traumatic brain injury, sleep apnea and Parkinson's disease. The Alzstatin platform focuses on developing disease-modifying and preventive drug candidates for early treatment of
Alzheimer's disease and comprises two drug projects. Painless is the company's research platform in the field of pain and contains two projects: ACD440, which is a drug candidate in the clinical
development phase for the treatment of neuropathic pain, and TrkA-NAM, which targets other types of severe pain in conditions such as arthritis. AlzeCure aims to pursue its own projects through
preclinical research and development through an early clinical phase and is continually working on business development to find suitable solutions for license agreements with other pharmaceutical
companies.
FNCA Sweden AB is the company's Certified Adviser. For more information, please visit www.alzecurepharma.se
Lesen Sie auch
About Alzstatin®
AlzeCure's disease-modifying research platform, Alzstatin, consisting of disease-modifying and preventive drug candidates, focuses on reducing the production of toxic amyloid beta (Aβ), such as
Aβ42, in the brain. Aβ42 plays a key pathological role in Alzheimer's and begins to accumulate in the brain years before clear symptoms develop. The drug candidates in the Alzstatin platform
modulate the function of the enzyme gamma secretase. Gamma secretase acts like a pair of scissors and cuts Aβ42 out from a longer protein known as APP. The sticky Aβ42 clumps together giving rise
to the amyloid plaque so typical of Alzheimer's disease. The candidates in the Alzstatin platform affect enzyme function so that it instead cuts out shorter forms of the Aβ peptide, Aβ37 and Aβ38,
which in addition to them not being sticky and not forming aggregates, also have a restrictive effects on Aβ42 aggregates already formed. This means the drug candidates in the Alzstatin platform
have two separate but synergistic effects that together contribute to a stronger anti-amyloidogenic - and thus more potent - disease-modifying effect. This specific mechanism of action
differentiates it from biological therapies, e.g. antibodies. Moreover, small molecules such as Alzstatin, have several other advantages, including easy and non-invasive administration as tablets
or capsules. Small molecules will also generally pass more readily through the blood-brain barrier to reach its target, the brain.